



## The Native Antigen Company Introduces Custom Service for Influenza Antigens

*Bespoke custom contract service offers rapid access to broad range of high-quality antigen panels for influenza A and B viruses*

**Oxford, UK, 19 August 2020:** The Native Antigen Company (now part of LGC's Clinical Diagnostics Division), one of the world's leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the introduction of its custom contract service to rapidly develop antigen panels for influenza A and B viruses. This new service offers scientists access to high-quality proteins from emerging seasonal and pandemic influenza strains, to support ongoing research and development of diagnostics and vaccines.

The Native Antigen Company provides custom contract services to develop panels of the influenza antigens from a wide range of virus strains and subtypes using its proprietary HEK293 mammalian expression system (VirtuE), which is able to introduce proper protein folding and full glycosylation to closely mimic naturally occurring proteins. The Company has already used this recombinant protein expression system to successfully develop a range of haemagglutinin and neuraminidase proteins for influenza A and B viruses, both of which spread routinely in humans and are responsible for seasonal flu epidemics each year. Its custom contract service could help researchers working with specific strains of influenza gain rapid access to highly purified proteins to conduct detailed assessments of immune responses with diagnostics, including vaccination responses to particular strains.

**Dr Andy Lane, Commercial Director, The Native Antigen Company, said:** *"Understanding existing influenza strains and having access to the corresponding antigens is vital to help distinguish infection from that of other respiratory diseases, and to enable accurate diagnosis and treatment. The Native Antigen Company is pleased to extend its custom contract service offering to now include the rapid development of influenza A and B antigens. We have worked hard to ensure our development capabilities can keep pace with emerging influenza strains and are proud to be able to produce a broad spectrum of high-quality proteins within a matter of weeks."*

For more information about The Native Antigen Company's influenza services, please visit:  
<https://thenativeantigencompany.com/influenza-services-landing-page/>

**ENDS**

**Notes to Editors**



*The Native Antigen Company's  
influenza antigens*

For a high-resolution image please contact Zyme Communications.

**For further information please contact:**

The Native Antigen Company  
Dr Andy Lane  
Tel: +44 (0)1865 595230  
Email: [alane@thenativeantigencompany.com](mailto:alane@thenativeantigencompany.com)

Zyme Communications  
Dr Michelle Ricketts  
Tel: +44 (0)7789 053885  
Email: [michelle.ricketts@zymecommunications.com](mailto:michelle.ricketts@zymecommunications.com)

*To opt-out from receiving press releases from Zyme Communications please e-mail [info@zymecommunications.com](mailto:info@zymecommunications.com). To view our privacy policy, please [click here](#).*

**About The Native Antigen Company** [thenativeantigencompany.com](http://thenativeantigencompany.com)

The Native Antigen Company is one of the world's leading suppliers of reagents that enable research into vaccine development and diagnostics for emerging and endemic infectious diseases. The Native Antigen Company specialises in the development and manufacture of native and recombinant viral and bacterial antigens, antibodies and immunoassays, alongside bespoke product development and custom manufacturing using its proprietary mammalian cell expression system.

The Native Antigen Company's team have decades of experience in the isolation and purification of native antigens and high-yield mammalian cell expression systems, ensuring conformity to native type. The Company's high-quality reagents have been widely adopted by leading pharmaceutical, *in vitro* diagnostic assay manufacturers, and academic groups in cutting-edge vaccine research and serology, where correct folding and glycosylation are vital.

The Native Antigen Company prides itself on an ethical and sustainable approach, exemplified by its use of 100% renewable energy and recycled packaging wherever possible, and building honest and transparent relationships with its customers and collaborators.

Founded in 2010, The Native Antigen Company is located in Oxford (UK) and has a global network of distributors.

Follow The Native Antigen Company on Twitter [@nativeantigen](https://twitter.com/nativeantigen) and LinkedIn [@The Native Antigen Company](https://www.linkedin.com/company/the-native-antigen-company/)

**About LGC Clinical Diagnostics** <https://www.lgcgroup.com/who-we-serve/healthcare/clinical-diagnostics/>

LGC's Clinical Diagnostics Division develops and manufactures a comprehensive portfolio of catalogue and custom-developed diagnostic quality solutions and component materials for the extended life sciences industry. We partner with IVD assay developers, and pharmaceutical, CRO and academic institutions in commercialization activities across the entire diagnostic pipeline - from concept and early stage research, through expedited product development and onwards into routine clinical use. Laboratorians and diagnostic professionals across disciplines of clinical chemistry, immunochemistry, serology, molecular diagnostics and clinical genomics rely on LGC's products to support accurate and reliable diagnostic results.

Our operating entities include [SeraCare Life Sciences](#) and [Maine Standards Company](#), which are *in vitro* diagnostics (IVD) manufacturers of quality measurement tools (calibrators, controls, linearity, EQA/PT, biological materials) and The Native Antigen Company, which is a manufacturer and supplier of viral antigens. Our 300+ employees operate FDA-registered and ISO 13485-accredited facilities in Maine, Massachusetts and Maryland, USA, and an ISO 9001-accredited facility in Oxford, UK.

Each day, our world-class staff, scientific expertise, operational efficiency and superior quality systems are ready to support the range of advanced technologies that collectively improve patient outcomes - from the widely adopted and established through to cutting-edge NGS and precision diagnostics.